Cargando…

Differences in and verification of genetic alterations in chemotherapy and immunotherapy for metastatic melanoma

Background: Metastatic melanoma has poor therapeutic response and may present resistance to chemotherapy or immunotherapy. Significant differences are observed in the survival time of patients with metastatic melanoma based on the administration of chemotherapy or immunotherapy; thus, we have explor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Yang, Gao, Yuling, Chu, Weiling, Lv, Jianjian, Li, Zhi, Shi, Tongxin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580330/ https://www.ncbi.nlm.nih.gov/pubmed/34675134 http://dx.doi.org/10.18632/aging.203640

Ejemplares similares

Immunotherapy Potentiates the Effect of Chemotherapy in Metastatic Melanoma—A Retrospective Study
por: Hadash-Bengad, Reut, et al.
Publicado: (2020)

Verification of EZH2 as a druggable target in metastatic uveal melanoma
por: Jin, Bei, et al.
Publicado: (2020)

Complications of sequential immunotherapy in metastatic melanoma
por: Bufalino, Shams, et al.
Publicado: (2015)

Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma
por: Mangin, Marie‐Alix, et al.
Publicado: (2021)

Outcomes From Cytotoxic Chemotherapy Following Progression on Immunotherapy in Metastatic Melanoma: An Institutional Case-Series
por: Gaughan, Elizabeth M., et al.
Publicado: (2022)

Current status and perspectives in immunotherapy for metastatic melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2018)

Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma
por: Nyakas, M., et al.
Publicado: (2019)

Mixed Response to Immunotherapy in Patients with Metastatic Melanoma
por: Rauwerdink, Daan Jan Willem, et al.
Publicado: (2020)

Combined Immunotherapy in Metastatic Melanoma with Unknown Primary
por: Khan, Yasir, et al.
Publicado: (2019)

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma
por: Wang, Zhi-long, et al.
Publicado: (2020)

Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
por: Yu, Chune, et al.
Publicado: (2019)

Antibody-Based Immunotherapy: Alternative Approaches for the Treatment of Metastatic Melanoma
por: Biteghe, Fleury Augustin Nsole, et al.
Publicado: (2020)

Retreatment of chemotherapy-resistant metastatic choriocarcinoma with immunotherapy
por: Wong, Adriana J., et al.
Publicado: (2022)

Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma
por: Keller, Hilary R., et al.
Publicado: (2017)

Efficacy of Immunotherapy in Patients with Metastatic Mucosal or Uveal Melanoma
por: Mignard, Claire, et al.
Publicado: (2018)

Significance of metastatic topography for the immunotherapy of cutaneous and ocular melanomas
por: Săftescu, Sorin, et al.
Publicado: (2020)

Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma
por: Krimphove, Marieke J., et al.
Publicado: (2019)

A nano-enhanced vaccine for metastatic melanoma immunotherapy
por: Salotto, Katelyn E., et al.
Publicado: (2022)

Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients
por: Ramos, Romela Irene, et al.
Publicado: (2020)

Verification of genetic differences and immune cell infiltration subtypes in the neuroblastoma tumour microenvironment during immunotherapy
por: Qian, Bo, et al.
Publicado: (2022)

Modification of the Tumor Microenvironment Enhances Anti-PD-1 Immunotherapy in Metastatic Melanoma
por: Shi, Guilan, et al.
Publicado: (2022)

Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma.
por: Thatcher, N., et al.
Publicado: (1977)

Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions
por: Ralli, Massimo, et al.
Publicado: (2020)

Association of Sociodemographic Factors With Immunotherapy Receipt for Metastatic Melanoma in the US
por: Moyers, Justin T., et al.
Publicado: (2020)

The Promise of Liquid Biopsy to Predict Response to Immunotherapy in Metastatic Melanoma
por: Fattore, Luigi, et al.
Publicado: (2021)

Checkpoint Inhibitors Immunotherapy in Metastatic Melanoma: When to Stop Treatment?
por: De Risi, Ivana, et al.
Publicado: (2022)

A Rare Case of Metastatic Uveal Melanoma Responding to Immunotherapy
por: Fadel, Celine A, et al.
Publicado: (2022)

Genetic alterations in peritoneal metastatic tumors predicted the outcomes for hyperthermic intraperitoneal chemotherapy
por: Nguyen, Quynh-Anh, et al.
Publicado: (2023)

Editorial: Screening and verification of new targets for CAR-T immunotherapy in cancer
por: Su, Yang, et al.
Publicado: (2023)

Screening and Verification of Molecular Markers and Genes Related to Salt-Alkali Tolerance in Portunus trituberculatus
por: Zhang, Wen, et al.
Publicado: (2022)

Genetic alterations driving metastatic colony formation are acquired outside of the primary tumour in melanoma
por: Werner-Klein, Melanie, et al.
Publicado: (2018)

Is there still a role for cytotoxic chemotherapy after targeted therapy and immunotherapy in metastatic melanoma? A case report and literature review
por: Simon, Aurélien, et al.
Publicado: (2017)

The genetic evolution of metastatic uveal melanoma
por: Shain, A. Hunter, et al.
Publicado: (2019)

Ipilimumab, a Promising Immunotherapy with Increased Overall Survival in Metastatic Melanoma?
por: Piérard, Gérald E., et al.
Publicado: (2012)

Regression of pigmented lesions in a patient with metastatic melanoma treated with immunotherapy
por: Schwager, Zachary, et al.
Publicado: (2018)

Chronic granulomatous reaction in patients receiving vaccine immunotherapy for metastatic melanoma
por: Aria, Alexander B., et al.
Publicado: (2017)

Eruptive squamous cell carcinomas in metastatic melanoma: An unintended consequence of immunotherapy
por: Haraszti, Samantha, et al.
Publicado: (2019)

Acute hypophysitis secondary to nivolumab immunotherapy in a patient with metastatic melanoma
por: Kuru, Sugabramya, et al.
Publicado: (2017)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives
por: Middleton, Mark R., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pbg02le80fqvfp2n5bibih4qrh